Quantcast
Last updated on April 18, 2014 at 6:54 EDT

Latest PLX5568 Stories

2008-09-04 09:00:08

US-based drug discovery and development company Plexxikon has started a Phase I human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs pain as well as polycystic kidney disease. Dosing has been completed in the first cohort of healthy volunteer subjects in the single ascending dose, double-blind, placebo-controlled trial, which will enroll approximately 30 subjects. This study will be followed by a...